Clinical Trial Update: Safety Study of IMC-18F1,to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy [Phase 1]

View source ↗

Summary

A completed Phase 1 safety study evaluating IMC-18F1 in patients with advanced solid tumors that no longer respond to standard therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• IMC-18F1

Snippet

Sponsor: Eli Lilly and Company | Conditions: Advanced Solid Tumors | Phase 1 | Status: COMPLETED